News headlines about BioScrip (NASDAQ:BIOS) have been trending positive recently, Accern Sentiment reports. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. BioScrip earned a daily sentiment score of 0.33 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.5449973419805 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the media stories that may have effected Accern’s rankings:
- BioScrip (BIOS) to Release Quarterly Earnings on Thursday (americanbankingnews.com)
- BioScrip, Inc. (BIOS) -Healthcare stock Financial Statistics – Nasdaq Fortune (press release) (nasdaqfortune.com)
- BioScrip (BIOS) Downgraded to Hold at BidaskClub (americanbankingnews.com)
- BioScrip Inc (BIOS) Receives Consensus Rating of “Buy” from Analysts (americanbankingnews.com)
- Lookout for these Two stocks: BioScrip, Inc. (NASDAQ:BIOS), Taseko Mines Ltd. (NYSE:TGB) – The Oracle Examiner (oracleexaminer.com)
A number of equities analysts have weighed in on the stock. BidaskClub lowered shares of BioScrip from a “buy” rating to a “hold” rating in a research report on Friday, January 26th. Zacks Investment Research upgraded shares of BioScrip from a “sell” rating to a “hold” rating in a research report on Wednesday, January 10th. ValuEngine upgraded shares of BioScrip from a “strong sell” rating to a “sell” rating in a research report on Thursday, November 9th. Finally, SunTrust Banks reiterated a “buy” rating and set a $3.00 target price on shares of BioScrip in a research report on Friday, November 3rd. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $3.63.
Shares of BioScrip (NASDAQ:BIOS) opened at $2.93 on Thursday. BioScrip has a fifty-two week low of $1.35 and a fifty-two week high of $3.39. The stock has a market cap of $376.17, a PE ratio of -4.73 and a beta of 0.19. The company has a debt-to-equity ratio of -6.11, a current ratio of 1.91 and a quick ratio of 1.60.
ILLEGAL ACTIVITY NOTICE: This news story was originally posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://www.thelincolnianonline.com/2018/02/22/bioscrip-bios-earns-daily-news-sentiment-rating-of-0-33.html.
BioScrip Company Profile
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.